洞察市场格局
解锁药品研发情报

客服电话

400-9696-311
医药数据查询

首页 临床进展 Can dermatological tarcolimus 0.1 % ointment be used for treatment of spring catarrh what is its efficacy and safety profile

【ChiCTR2000031929】Can dermatological tarcolimus 0.1 % ointment be used for treatment of spring catarrh what is its efficacy and safety profile

查看原文
立即下载
基本信息
登记号

ChiCTR2000031929

试验状态

结束

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2020-04-15

临床申请受理号

/

靶点

/

适应症

春季角膜结膜炎

试验通俗题目

Can dermatological tarcolimus 0.1 % ointment be used for treatment of spring catarrh what is its efficacy and safety profile

试验专业题目

Comparison of efficacy of dermatological 0.1% tacrolimus in treatment on vernal keratoconjunctivitis

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

52250

联系人通讯地址
请登录查看
临床试验信息
试验目的

Tacrolimus has been used in different concentrations for ophthalmic use. It is used in 0.1 % as well as in 0.03% concentrations. Some studies claim it is more effective in 0.1 % concentration. In most studies tacrolimus is studied in bid dose, we intend to check its efficacy in HS dose.

试验分类
请登录查看
试验类型

单臂

试验分期

上市后药物

随机化

N/A

盲法

N/A

试验项目经费来源

No funding

试验范围

/

目标入组人数

50

实际入组人数

/

第一例入组时间

2019-07-01

试验终止时间

2020-03-31

是否属于一致性

/

入选标准

Inclusion criteria were all the pediatric patients of severe VKC, unmanageable with conventional treatment (anti-histamines/mast cell stabilizers/NSAIDS/steroids) or patients showing recurrence after discontinuation of steroids or having steroid-induced complications.；

排除标准

Exclusion criteria were any coexisting ocular disorders such as conjunctival or corneal diseases, ocular infections, uveitis, Stevens Johnson syndrome, contact lens usage, history of ocular surgery. Informed consent was taken and all the patients were explained about the study.；

研究者信息
研究负责人姓名
请登录查看
试验机构

Self-sponsored

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

52250

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

Self-sponsored的其他临床试验

更多

巴基斯坦古吉兰瓦拉医学院的其他临床试验

更多

最新临床资讯

更多
摩熵医药企业版
50亿+条医药数据随时查
7天免费试用
体验产品